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Objective: To evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with 
schizophrenia.
Methods: Data from a double-blind, randomized study demonstrating the efﬁ  cacy of 
aripiprazole and olanzapine were used to observe new incidence of metabolic syndrome 
(26-week therapy) and to model the risk of developing diabetes over 5 years of therapy. 
Cumulative incidence of metabolic syndrome was compared using Kaplan–Meier estimates; 
diabetes risk was estimated using a validated, general population risk-prediction model. 
Economic assessment was conducted from the third-party payer perspective by evaluating 
pharmacotherapy costs of treating schizophrenia and medical costs associated with treating 
adverse metabolic effects in a hypothetical cohort of 1000 patients. Resource utilization and 
costs were derived from the underlying study and published data, using a 3% rate to discount 
costs and beneﬁ  ts.
Results: For the patients switched from olanzapine to aripiprazole, treatment with 
aripiprazole was a dominant cost-saving strategy. Use of aripiprazole avoided 184 events 
of metabolic syndrome over 26 weeks of treatment, contributing to a real-world (RW) cost 
savings of  2.53 per patient and a total savings of approximately  465.52 over a 5-year 
period. For the same cohort, the risk-prediction model indicated that 34 occurrences of 
diabetes could be avoided over 5 years, corresponding to a RW cost savings of  56.86 
per patient and a total saving of approximately  1,933.24. These savings reflect avoided 
costs in treating adverse metabolic events and comparable costs in the acquisition of 
aripiprazole.
Conclusions: Maintenance aripiprazole therapy offers medical and economic beneﬁ  ts over 
olanzapine, reﬂ  ected by reduced incidence of metabolic syndrome and diabetes and associated 
lower costs.
Keywords: schizophrenia, cost-consequences, apripiprazole, olanzapine, metabolic syndrome, 
diabetes
Introduction
Schizophrenia is a chronic psychiatric disorder characterized by hallucinations, 
delusions, negative symptoms, and disruptive thoughts and behaviors that typically 
arise during late adolescence or early adulthood (Thompson et al 2004). It affects 
approximately 1% of the US population (Ryan 1991) and is estimated to have a global 
prevalence of 0.14%–0.46% (Jablensky 2000).
The newer, second-generation antipsychotics (SGAs), also referred to as atypical 
antipsychotics, are thought to represent a signiﬁ  cant advance over conventional 
ﬁ  rst-generation antipsychotics (FGAs) in the treatment of patients with schizophrenia. Neuropsychiatric Disease and Treatment 2008:4(5) 968
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Speciﬁ  cally, SGAs have a lower propensity to cause extra-
pyramidal symptoms (EPS) (eg, dystonia, tardive dyskine-
sia, akathisia and parkinsonism), which limit the safety of 
and long-term compliance with FGAs (Lakka et al 2002; 
Ryan and Thakore 2002). However, some SGAs have been 
associated with various adverse metabolic effects, such as 
glucose dysregulation, dyslipidemia and signiﬁ  cant weight 
gain (Hughes et al 1986; de Leon et al 1995; Allison et al 
1999; Susce et al 2005). Together with hypertension, these 
abnormalities comprise metabolic syndrome (Dixon et al 
2000), which is associated with an increased risk for diabetes 
and coronary heart disease (CHD) (Lakka et al 2002; Ryan 
and Thakore 2002).
In addition to the increased risk for metabolic syndrome 
with certain SGAs, patients with schizophrenia already have 
increased risk factors for CHD, eg, smoking (Hughes et al 
1986; de Leon et al 1995) and obesity (Allison et al 1999; 
Susce et al 2005). Moreover, patients with schizophrenia 
have a 5-fold higher risk of myocardial infarction than 
the general population (Enger et al 2004) and are also at 
increased risk for diabetes, independent of medication usage 
(Dixon et al 2000; Wirshing 2004). Recent ﬁ  ndings from 
the CATIE study report a 40% prevalence of metabolic 
syndrome in patients with schizophrenia (McEvoy et al 
2005). Consequently, the metabolic proﬁ  les of SGAs are 
important when considering treatment options for this patient 
population (Wirshing 2004). Given the signiﬁ  cant social 
and economic costs associated with treating patients with 
diabetes (Lucioni et al   2000; Lucioni et al 2001; Ridker 
et al 2003), existing differences in metabolic proﬁ  les must 
be considered when choosing a pharmacological intervention 
for schizophrenia (Nasrallah 2002).
In Italy the average yearly total cost of a type 2 diabetes 
patient is about  3,136 per patient, while the estimated cost of 
the whole type 2 diabetes population is about  5,423 million. 
Direct costs account for 95.5% of the total. On the whole, 
they correspond to 6.65% of the total health care expenditure 
(public plus private) (Lucioni et al 2000, 2001). The substan-
tial economic and social impacts of the disease result from 
high mortality rates (particularly among young adults), loss 
of employment, homelessness, family burden, and excessive 
use of inpatient health services, social services and housing 
services (Guest and Cookson 1999; Knapp 2000; Enger et al 
2004; Folsom et al 2005).
The SGA aripiprazole has been shown to have clinical 
efﬁ  cacy similar to that of other SGAs and FGAs (Kane et al 
2002; Marder et al 2003; McQuade et al 2004). Moreover, 
aripiprazole has not been associated with the same degree 
of  EPS observed with the older FGA haloperidol (Kane et al 
2002; Marder et al 2003; Allochis et al 2008) or with weight 
gain observed with many of the other SGAs (McQuade et al 
2004; ADA/APA/AACE/NAASO 2004).
The objective of this analysis was to conduct an economic 
evaluation of aripiprazole versus olanzapine for the treatment 
of schizophrenia in the Italian setting from a third-party 
payer perspective (Servizio Sanitario Nazionale – National 
Health Service [NHS]). Speciﬁ  cally, assuming equal clini-
cal efﬁ  cacy between the two agents, we will evaluate the 
pharmacotherapy costs of treatment for schizophrenia and 
the medical costs of treating adverse metabolic effects (eg, 
dyslipidemia, diabetes).
Methods
The model is developed to show the potential short-run and 
long-run cost savings in terms of incidence of metabolic syn-
drome and a lower risk of diabetes generated for a simulated 
cohort of 1000 patients with schizophrenia when treated with 
aripiprazole compared with olanzapine. These data were 
elaborated from a 26-week, multicenter, double-blind study 
comparing a ﬂ  exible dose of aripiprazole 15–30 mg/day 
(n = 155) with a ﬂ  exible dose of olanzapine 10–20 mg/day 
(n = 159) on changes in weight and efﬁ  cacy in the manage-
ment of schizophrenia (McQuade et al 2004). The results 
of this study demonstrated that efﬁ  cacy was comparable 
between treatment arms, as evidenced by sustained improve-
ment in Positive and Negative Syndrome Scale (PANSS) 
scores, Clinical Global Impressions – Improvement scores, 
and in responder rates throughout the study. A sub-sample of 
patients (314 out of  317) from this trial (McQuade et al 2004) 
who had complete metabolic data in addition to the weight 
data was used to assess metabolic syndrome changes during 
the 26-week in-trial therapy period, and to model the risk of 
diabetes in the ensuing 5 years after the formal trial period.
Metabolic syndrome was deﬁ  ned as the presence or 
clinically meaningful exacerbation of three of ﬁ  ve National 
Cholesterol Education Program (NCEP) Adult Treatment 
Panel (ATP) III risk factors (NCEP 2001). In addition, a 
combination deﬁ  nition that consisted of NCEP ATP III 
criteria and the clinically meaningful percentage change from 
baseline of those criteria were established (Table 1). Given 
that waist circumferences for most patients enrolled in the 
study were unavailable, the working deﬁ  nition involved the 
use of body mass index (BMI) rather than waist circumfer-
ence to deﬁ  ne abdominal obesity. This is supported by several 
metabolic studies in which BMI served as a surrogate for 
waist circumference (Ridker et al 2003; Sattar et al 2003; Neuropsychiatric Disease and Treatment 2008:4(5) 969
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Ford 2004) and by a demonstrated positive correlation 
between these measures in another study (Lean et al 1995).
Model structure
In this model, treatment with either aripiprazole or olanzapine 
was assessed for metabolic disturbances over the 26 weeks of 
the study, and simulated to provide a comparison of estimated 
incidence rates of diabetes over 5 years, with corresponding 
estimated direct costs of care (Figure 1). A comparative eco-
nomic evaluation was conducted based on aripiprazole and 
olanzapine having comparable efﬁ  cacy. Post-hoc analyses of 
PANSS scores in the present study support this assumption. 
Table 1 Metabolic syndrome deﬁ  nitions
Adult Treatment Panel III Deﬁ  nition (Dixon et al 2000) Modiﬁ  ed Deﬁ  nition
Waist circumference 40 inches (male) and 35 inches (female) 7% increases in BMI from baseline AND BMI 25 kg/m2*
HDL-C 40 mg/dL (male) and 50 mg/dL (female) 15% decrease in HDL-C from baseline AND HDL-C 40 mg/dL†
DBP 85 mmHg or SBP 130 mmHg 8 mmHg increase in DBP from baseline AND DBP 85 mmHg
OR
12 mmHg increase from baseline in SBP AND SBP 130 mmHg‡
Fasting triglycerides 150 mg/dL 15% increase from baseline from baseline in fasting triglycerides AND 
fasting triglycerides 150 mg/dL
Fasting plasma glucose 110 mg/dL 20% increase from baseline in fasting plasma glucose AND fasting 
plasma glucose 110 mg/dL§
*BMI was used rather than abdominal circumference because both are good predictors of metabolic outcomes and the former was directly related to the primary endpoint 
of the study.   Waist circumference was not always available.
†A simpliﬁ  cation was made to consider values 40 mg/dL for men and women.
‡8 mmHg and 12 mmHg constitute the standard deviations for DBP and SBP measurements, respectively. Hence, any changes beyond these values may be considered true 
elevations in blood pressure.
§Some patients did not have a fasting blood glucose measurement at baseline. For those patients, non-fasting values were used at baseline and subsequent visits.
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; DBP,  diastolic blood pressure; SBP,  systolic blood pressure.
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Besides assuming equal efﬁ  cacy between aripiprazole and 
olanzapine, it was assumed that compliance with therapy 
was not affected by the occurrence of adverse events (AEs), 
including weight gain. Furthermore, the estimated risk for 
diabetes was based on changes from baseline to week 26 
observed during the 26-week study period.
Estimation of diabetes incidence
The impact of therapy on the risk factors associated with 
the development of diabetes and its projected incidence 
were calculated for aripiprazole and olanzapine using a 
risk-prediction model developed by Stern et al (2002). This 
multivariate model used data from the San Antonio Heart 
Study (Burke et al 1999) to predict the risk of developing 
type 2 diabetes in 7.5 years. Variables in the model include 
patient characteristics (age, sex, ethnicity, and family history 
of diabetes) and laboratory values (fasting glucose, HDL, 
BMI, and systolic blood pressure). The authors found this 
risk-prediction model to be a viable alternative to the glucose 
tolerance test in predicting the risk of diabetes.
The current study incorporated patient data from the 
clinical study of McQuade et al (2004) into the diabetes risk-
prediction model developed by Ray et al (2004). The expected 
incidence of diabetes was projected for a 5-year period, but 
it was assumed that the measures affecting the outcomes of 
interest would not change further after week 26; it is actually 
likely that a medication that causes a metabolic parameter, such 
as body weight, to change over 26 weeks will continue to do so 
beyond that period (Nemeroff 1997; Henderson et al 2000).
To correct for any nominal differences in the variables 
at baseline between treatment arms, an analysis adjusting 
for baseline risk (analysis of covariance [ANCOVA]; proc. 
GLM, SAS version 8.1; SAS Institute, Cary, NC) was 
performed. After calculating the risk at 7.5 years (r), annual 
risk levels at time (t) between 0 and 5 years were approxi-
mated according to the following equation:
Diabetes risk (t) = 1 – (1 – r)(t/7.5)
Estimation of costs
Economic analysis was conducted from the third-party payer 
perspective (NHS) by evaluation of the pharmacotherapy 
costs of treating schizophrenia and the direct costs of treating 
metabolic AEs and/or diabetes. Resource utilization and costs 
were derived from the clinical study and from published data 
(Lucioni et al 2000; Lucioni et al 2001). An annual discount 
rate of 3% was used to discount the annual costs and beneﬁ  ts 
beyond the ﬁ  rst year of assessment.
Unit costs for antipsychotic drug were obtained from the 
Informatore Farmaceutico 2007 and were applied to the dosages/
strengths used. The daily costs were used to calculate drug costs 
for 26 weeks of therapy (Table 2). The cost of diagnosing and 
treating metabolic syndrome was estimated by assigning unit 
resource costs to physician visits, laboratory tests (eg, blood 
glucose and lipids), and drugs for treating hyperlipidemia (eg, 
statins, ﬁ  brates, niacin), hyperglycemia (oral antidiabetic agents) 
and hypertension (antihypertensives). The costs of diagnosing 
and treating the metabolic syndrome were estimated by assign-
ing unit resource costs and drug costs (Table 3).
The cost of initializing treatment for metabolic syndrome, 
including ofﬁ  ce visits, tests and medications, was calculated 
for all patients. The direct cost estimate of treating diabetes 
was calculated according to the 1997 American Diabetes 
Association published estimates on medical treatment for 
patient with type 2 diabetes mellitus (Graves and Gillum 1996; 
Schappert 1996; Strahan 1996, 1997; ADA 1998); these data 
Table 2 Direct medical costs for management of metabolic syndrome
Cost type EUR € Comment and source
Aripiprazole, 15 mg €5.02 Informatore Farmaceutico, 2007
Olanzapine, 10 mg €5.02 Informatore Farmaceutico, 2007
Unit resource costs Physician visits €23.00 2006 National Tariff Nomenclator, Health Ministry
Glucose tests €1.29 2006 National Tariff Nomenclator, Health Ministry
Lipid test €3.15 Includes HDL and triglycerides, 2006 National 
Tariff Nomenclator, Health Ministry
Drug costs Hyperlipidemic agents See comment Weighted average price/day for statins (€0.79), 
ﬁ  brates (€0.52) or niacin (€1.70) using weights 
of 0.4, 0.3 and 0.3, respectively (OSMED 2007)
Oral hypoglycemic agents €0.20 OSMED, 2007
Antihypertensives €0.26 OSMED, 2007
Abbreviations: HDL, high-density lipoprotein.Neuropsychiatric Disease and Treatment 2008:4(5) 971
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were modiﬁ  ed taking into account the Italian CODE Study and 
the BRESCIA Study (Lucioni et al 2000, 2001; Scarcella et al 
2006), which included inpatient and outpatient visits (includ-
ing home health, hospice, and nursing home care and emer-
gency room visits), tests, diagnostic procedures, other health 
services and diabetic drug treatment in Italy. The ISTAT 
medical care component of the Consumer Price Index was 
applied to approximate the time frame from which the current 
data originate at year 2007 (Italian inﬂation rates 2007).
Statistical analysis
Kaplan–Meier survival analysis was performed to estimate 
the cumulative incidence of metabolic syndrome (using the 
modiﬁ  ed deﬁ  nition described in Table 1) over the course of 
the 26-week study. The log-rank test was used to test the 
difference between the survival functions. The risk for diabe-
tes was estimated based on vital signs, laboratory values, and 
demographic data collected at the baseline and at week 26 visits 
using a validated, general population risk model developed by 
Stern et al (2002). To correct for any nominal differences in 
these factors between treatment groups at baseline, ANCOVA 
was performed to adjust for baseline risk. After calculating the 
risk at 7.5 years, annual risk levels between 0 and 5 years were 
approximated for each treatment group (Stern et al 2002).
Sensitivity analysis
Sensitivity analysis was performed according to clinical study 
(CT)-based and the RW dose regimens. Because this was a 
Table 3 Resource utilization: type II diabetes
Diabetic treatment Units Unit cost Value Source Comments
Hospitalizations ALOS/No 
of hosps
Per diem/DRG cost €4,774.13 DM 12/09/2006 DRG 294
 Emergency  room 
 visits
No of visits Cost per visit €34.50 DM 12/09/2006 Cod 89.7 + 50%
Physician visits
  Physician visit No of visits Cost per consult €13.03 Lucioni et al 2000 and 2001
 Hospital  outpatient 
 visit
No of visits Cost per consult €23.00 DM 12/09/2006
Test/Diagnostic 
procedures
  Oral glucose test No of tests Cost per test €30.57 DM 12/09/2006 Cod 90.28.5
 Glycosylated 
 Hemoglobin
No of tests Cost per test €10.59 DM 12/09/2006 Cod 90.28.1
  Urinalysis No of tests Cost per test €2.07 DM 12/09/2006 Cod 90.44.3
  Vision test No of tests Cost per test €7.75 DM 12/09/2006 Cod 95.09.1
Other health care 
services
  Home health care No of visits Cost per visit €46.48 DM 12/09/2006 Cod 89.07
  Hospice care No of days Cost per visit €201.42 Deliberation of the Regional 
Council of Lombardy 
of 13/12/06 and nr. 4239 
of 28/02/2007
  Nursing home care No of days Cost per visit €166.67 Lombardy Region, Hospital 
of Busto Arsizio,   Varese
Drug therapy
  Sulfonylureas No of treatments Cost per treated patient €0.1831 Lucioni et al 2000 and 2001 €/die
  Biguanides No of treatments Cost per treated patient €0.0001 Lucioni et al 2000 and 2001 €/die
 Alpha-glucosidase 
 inhibitors
No of treatments Cost per treated patient €0.681 Lucioni et al 2000 and 2001 €/die
  Thiazodilinediones No of treatments Cost per treated patient €2.071 Lucioni et al 2000 and 2001 €/die
  Meglitinides No of treatments Cost per treated patient €0.036 Lucioni et al 2000 and 2001 €/die
  Insulin No of treatments Cost per treated patient €0.892 Lucioni et al 2000 and 2001 €/die
Abbreviations: ALOS, average length of stay; DM, Decreto Ministeriale [Ministerial Decree]; Cod, code; DRG, diagnosis-related group.Neuropsychiatric Disease and Treatment 2008:4(5) 972
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CT-based economic evaluation, the distributions of patients on 
different dose strengths (15–30 mg for aripiprazole, 10–20 mg 
for olanzapine) during the 26-week study were used in this 
economic evaluation. This enabled us to estimate a plausible 
range of costs for the simulated patient sample observed in the 
study, based on CT dose regimens and on those reﬂ  ecting RW 
regimens observed with patients in these dose ranges.
Results
The patient groups modeled had similar baseline demographic 
and metabolic characteristics (Table 4). Based on a Kaplan–
Meier survival analysis, aripiprazole was associated with a 
lower incidence of metabolic syndrome and a delayed onset of 
development of metabolic syndrome compared with olanzapine 
(Figure 2). The log-rank test found a statistically signiﬁ  cant dif-
ference (p = 0.011) between the two incidence functions with an 
estimated hazard ratio for aripiprazole versus olanzapine of 0.31 
(95% conﬁ  dence interval [95% CI]; 0.12, 0.77). At 26 weeks, 
the estimated cumulative incidence rates of new or worsening 
metabolic syndrome were 20.9% (± 7.8% [95% CI]) for olan-
zapine and 9.2% (± 5.5% [95% CI]) for aripiprazole.
Based on the estimated incidence rates, costs associated 
with the treatment of metabolic syndrome and pharmaco-
therapy for schizophrenia were determined. Compared with 
olanzapine, aripiprazole use was found to be a dominant 
cost-saving strategy for treating schizophrenia. Based on the 
estimated absolute risk reduction of 18.4%, aripiprazole use 
instead of olanzapine in a simulated cohort of 1000 patients 
resulted in the avoidance of 184 occurrences – new or wors-
ening cases – of metabolic syndrome after the 26 weeks of 
therapy until 1 year; this risk reduction reﬂ  ects the metabolic 
characteristics seen for each drug in clinical studies and 
observational studies (Newcomer 2005). Avoidance of these 
cases would contribute to a cost savings of  2.53 per patient 
and a total savings of approximately  465.52 (Table 5).
When considering diabetes prevention, aripiprazole was 
also a dominant cost-saving strategy. In the simulated cohort of 
1000 patients, the values with aripiprazole for 26 weeks showed 
the avoidance of 34 events of diabetes over 5 years (18 in dis-
counted scenario), resulting in a total cost savings of  1,926.65 
( 966.77 in discounted scenario). In these scenarios, the cost 
savings reﬂ  ect lower treatment costs of metabolic syndrome 
and diabetes, and lower aripiprazole acquisition costs.
Discussion
These results highlight the medical and economic beneﬁ  ts 
from maintenance therapy with aripiprazole compared with 
olanzapine, reﬂ  ected by the reduced incidences of metabolic 
Table 4 Characteristics of patients observed at baseline and change at Week 26 (LOCF) in the clinical study
Aripiprazole 15–30 mg/day (n = 155)a Olanzapine 10–20 mg/day (n = 59)a
Characteristic n Baseline Difference 
at week 26
n Baseline Difference 
at week 26
p-value
Mean age, y (SE) 155 38.72 (0.86) – 159 38.13 (0.88) – –
Male, n (%) 155 113 (73%) – 159 113 (71%) – –
Mean weight, kg (SE) 136 80.82 (1.84) –0.86 138 80.42 (1.85) 3.35 0.001
Mean body mass index, kg/m2 (SE) 156 27.6 (0.5) –0.10 161 27.7 (0.6) 0.8 0.001
Mean fasting serum glucose, mg/dL (SE) 107 89.88 (2.02) 2.68 115 91.68 (1.95) 3.22 NS
Mean HbA1c, % (SE) 144 5.50 (0.06) 0.02 145 5.56 (0.06) 0.11 NS
Mean total cholesterol, mg/dL (SE) 108 184.10 (4.06) –3.47 115 184.64 (3.94) 9.18 0.009
Mean LDL-C, mg/dL (SE) 108 107.83 (3.47) –1.43 114 110.33 (3.38) 5.04 NS
Mean HDL-C, mg/dL (SE) 108 44.00 (1.17) 2.7 114 43.69 (1.14) –0.37 0.019
Mean fasting triglycerides, mg/dL (SE) 108 162.44 (10.68) –20.20 114 159.36 (10.39) 17.07 0.012
aNot all measures were available for every patient.
Abbreviations: LOCF, last observation carried forward; NS, non-signiﬁ  cant; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; SE, standard error.
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Figure 2  Kaplan–Meier plot of incidence of metabolic syndrome (cumulative incidence 
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syndrome and diabetes, and lower total costs associated with 
aripiprazole treatment. Even though the efﬁ  cacy of aripiprazole 
and olanzapine was found to be comparable in the original clini-
cal trial (McQuade et al 2004), this analysis found aripiprazole 
to be more cost effective than olanzapine when metabolic side 
effects and their related treatment costs were accounted for. In 
this study, treatment costs (attributed to fewer metabolic AEs) 
and drug acquisition costs were lower with aripiprazole use.
The present analysis also found reduced incidence of 
new and worsening metabolic syndrome in patients treated 
with aripiprazole than those treated with olanzapine. The 
consequent projected risk for diabetes was also lower in 
aripiprazole-treated patients. These results are consistent 
with those of other studies in which olanzapine is associ-
ated with an increased attributable risk for diabetes over 
background rates (Newcomer 2005; Koro et al 2002; Leslie 
and Rosenheck 2004; Lambert et al 2005). In contrast, the 
incidence of metabolic syndrome and the projected risk for 
diabetes are not signiﬁ  cantly different between aripiprazole 
and placebo (Weiden et al 2003; L’Italien et al 2006). This 
suggests that the increased risk for diabetes projected in 
this study for patients on olanzapine may be due to some 
intrinsic quality of that drug, whereas aripiprazole-treated 
patients showed an incidence similar to the background rate 
for diabetes among patients with schizophrenia in general. 
Risk projections for diabetes presented previously were based 
on changes in metabolic parameters observed over 26 weeks 
(McQuade 2004) and were not extrapolated beyond that 
period, probably underestimating the full long-term beneﬁ  t of 
aripiprazole. However, it must be pointed out that McQuade’s 
study is a large comparative atypical study designed to show 
non-inferiority of aripiprazole versus olanzapine in over 
Table 5 Results: Direct medical costs and metabolic adverse effects avoided from over 26 weeks of aripiprazole therapy (model results 
based on McQuade et al 2004) – Base case scenario
Outcomes
Aripiprazole 
15 mg/die
Olanzapine 
10 mg/die
Aripiprazole 
substitution
ICER
Time horizon Metabolic 
events modeled
Total cost/
schizophrenia 
patient
Total cost* 
avoided/
schizophrenia 
patient
Events 
avoided/1000 
schizophrenia 
patients
Cost/metabolic 
syndrome 
avoided
26-week therapy Metabolic 
syndrome
€1,619.36 €1,621.89 −€2.53 Cost saving 184 −€13.79
5 years Type 2 diabetes 
(undiscounted)
€7,936.55 €7,993.41 −€56.86 Cost saving 34 −€1,678.18
5 years Type 2 diabetes 
(discounted 3%)
€7,315.83 €7,368.42 −€52.59 Cost saving 18 −€2,860.52
*Includes cost of antipsychotic therapy and the costs of treating metabolic syndrome and diabetes for the patients with these adverse effects.
Table 6 Sensitivity analysis: dose die increasing for aripiprazole and olanzapine
Outcomes
Aripiprazole 
20 mg/die
Olanzapine 
15 mg/die
Aripiprazole 
substitution
Time horizon Metabolic events modeled Total cost/
schizophrenia patient
Total cost* avoided/
schizophrenia patient
26-week therapy Metabolic syndrome €2,428.03 €2,430.80 −€2.76 Cost saving
5 years Type 2 diabetes (undiscounted) €11,830.19 €11,888.16 −€57.97 Cost saving
5 years Type 2 diabetes (discounted 3%) €10,904.86 €10,958.47 −€53.61 Cost saving
Aripiprazole 
30 mg/die
Olanzapine 
20 mg/die
26-week therapy Metabolic syndrome €3,236.71 €3,239.48 −€2.76 Cost saving
5 years Type 2 diabetes (undiscounted) €15,723.83 €15,781.80 −€57.97 Cost saving
5 years Type 2 diabetes (discounted 3%) €14,493.88 €14,547.49 -€53.61 Cost savingNeuropsychiatric Disease and Treatment 2008:4(5) 974
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700 subjects. In contrast with these results, we have to note 
that, according to a study by McCue (2007), olanzapine was 
signiﬁ  cantly more effective than aripiprazole: the relevance 
of these results must be considered in the context of certain 
limitations of our analysis.
In our simulation, BMI was used as reference parameter 
to assess the impact of metabolic syndrome and conversion 
to waist circumference was performed. It must be noted 
that the relationship between these two adiposity measures 
may not be so straightforward, as shown by Faulkner et al 
(2007), who developed a schizophrenia-speciﬁ  c conversion 
system from BMI to abnormal waist. The etiology of the 
increased prevalence of type 2 diabetes mellitus in psychiatric 
disorders is uncertain, and although it might be due to the 
weight gain associated with atypical antipsychotic agents, 
this hypothesis should be regarded cautiously, especially in 
light of the fact that schizophrenia may be an independent 
risk factor for diabetes mellitus (Ryan et al 2003; Graham 
et al 2008). Consequently, our simulation should probably be 
updated based on these considerations, though more robust 
clinical trials would be necessary to gain more insights into 
this question.
Estimated costs of therapy with both agents assumed 
100% compliance and an unchanged average daily dose 
for 5 years; chronic diseases associated with metabolic 
syndrome other than diabetes were not included in the cost 
calculations. Finally, the doses used do not reﬂ  ect RW 
regimens of the two drugs in clinical practice; treatment 
with RW doses might lead to different risks for metabolic 
consequences, although published studies showing a link 
between diabetes onset and RW use of olanzapine do not 
report a dose-dependent risk (Koro et al 2002; Sernyak et al 
2002). Nonetheless, the application of an RW dose would 
probably result in higher cost savings with aripiprazole, 
assuming a dose-independent AE proﬁ  le, as RW dosing is 
increased relatively more for olanzapine than for aripipra-
zole (Citrome et al 2007), resulting in a larger increase in 
medication cost for olanzapine. It must be pointed out that 
the model used in this study has a limitation that depends 
on the lack of information on aripiprazole’s behavior in 
terms of long-term treatment. If aripiprazole clinical efﬁ  -
cacy is related to an increase in RW dosing over time that 
is proportionally superior to that of olanzapine, the results 
of this study could be reversed, with olanzapine being more 
cost-effective. On the contrary, if aripiprazole use beyond 
the period considered does not increase more than or is the 
same as that of olanzapine, our economic analysis would 
prove aripoprazole’s advantage over olanzapine from a 
medical and economic point of view. To be able to conﬁ  rm 
either of the two hypotheses, a drug-utilization study for 
aripiprazole would be necessary.
Because of the difﬁ  culty in estimating the costs associated 
with weight gain (eg, use of weight-lowering adjunct therapy) 
from the payer’s perspective, these costs were not considered 
in this economic evaluation. However, weight gain and the 
indirect costs associated with it are certainly not inconse-
quential. Moreover, weight gain has a potential impact on 
metabolic syndrome, triglyceride levels, hypertension, CHD, 
stroke, and diabetes (Kurzthaler and Fleischhacker 2001; 
Brown 1998). In addition to these health risks among patients 
with schizophrenia, excessive weight gain can also cause 
quality-of-life impairment, increased relapse associated with 
non-compliance, and social withdrawal because of the stigma 
of obesity (Kurzthaler and Fleischhacker 2001).
The relevance of these results must be considered in 
the context of certain limitations. It should be emphasized 
that this work represents a cost-consequence analysis. The 
comparative study from which the incidence of metabolic 
syndrome was derived demonstrated a reduced incidence 
of new or worsening metabolic syndrome with aripiprazole 
than olanzapine. If metabolic syndrome was not prevented 
or treated, it was assumed that diabetes would develop in the 
projected number of patients. Finally, since the data used to 
develop our model were obtained from a study carried out in 
the US, one may doubt how representative these data might be 
for European patients (eg, different ethnicities). Nevertheless, 
this is a ﬁ  rst attempt and may be regarded as a ﬁ  rst step for 
developing studies more targeted to the European context.
The estimated avoidance of diabetes is a projection that 
must be conﬁ  rmed in a prospective long-term study. Another 
limitation is that the issue of persistence was not included 
in this model. The possibility of discontinuing or switching 
drugs – events that could possibly change the predicted risk 
of metabolic syndrome or diabetes – was not considered in 
this analysis. In conclusion, the use of aripiprazole can avoid 
incidences of metabolic syndrome and potentially diabetes, 
thereby improving patient health and lowering healthcare 
costs; the present data suggest that aripiprazole may be a 
beneﬁ  cial and cost-effective alternative to olanzapine, and 
more appropriate for patients at greatest risk of metabolic 
complications.
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